S. Calbo et al., Antitumor vaccination using a major histocompatibility complex (MHC) classI-restricted pseudopeptide with reduced peptide bond, J IMMUNOTH, 23(1), 2000, pp. 125-130
Synthetic peptides have raised a considerable interest in the fields of vac
cines and immunotherapy. The authors previously introduced modifications in
to the peptide backbone of the H-2K(d) restricted epitope CW3. One of these
pseudopeptides, C7, bound to K-d with an affinity identical to the parent
peptide and was recognized by T cells specific for the parent peptide. The
authors now show that this analog has an increased resistance to trypsin an
d displays an extended half-life in serum. The authors further tested its i
mmunogenicity both in vitro and in vivo and found that cytotoxic T lymphocy
tes (CTL) induced against the peptide analog recognize the parent peptide.
Moreover, analysis of T-cell receptor rearrangements by Immunoscope softwar
e revealed that C7-induced CTL display the hallmarks of the response agains
t the parental epitope CW3. Administration of the pseudopeptide into DBA/2
mice induces a protective immune response against a lethal challenge with t
umor cells expressing the parent peptide. Therefore, modifications in the b
ackbone of antigenic peptides can decrease protease susceptibility while pr
eserving immunogenicity. Such peptide analogues may therefore prove useful
for the development of new therapeutic tools aimed at eradicating pathogens
or tumors.